Mustang Stock Today

MBIO -  USA Stock  

USD 0.69  0.03  4.55%

Market Performance
0 of 100
Odds Of Distress
Less than 1
Mustang Bio is selling for 0.69 as of the 27th of May 2022. This is a 4.55 percent up since the beginning of the trading day. The stock's open price was 0.66. Mustang Bio has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Mustang Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2022 and ending today, the 27th of May 2022. Click here to learn more.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. The company has 92.58 M outstanding shares of which 3.78 M shares are now shorted by private and institutional investors with about 4.34 trading days to cover. More on Mustang Bio
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Mustang Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Mustang Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mustang Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Mustang Bio generated a negative expected return over the last 90 days
Mustang Bio has high historical volatility and very poor performance
Mustang Bio has some characteristics of a very speculative penny stock
Mustang Bio is unlikely to experience financial distress in the next 2 years
Net Loss for the year was (66.37 M).
Mustang Bio currently holds about 109.62 M in cash with (53.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Mustang Bio has a frail financial position based on the latest SEC disclosures
Roughly 21.0% of the company outstanding shares are owned by corporate insiders
Latest headline from Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 - BioSpace
Mustang Bio Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Mustang Bio SEC Filings
Mustang Bio SEC Filings Security & Exchange Commission EDGAR Reports
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Mustang Bio report their recommendations after researching Mustang Bio's financial statements, talking to executives and customers, or listening in on Mustang Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Mustang Bio. The Mustang consensus assessment is calculated by taking the average forecast from all of the analysts covering Mustang Bio.
Strong Buy5 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Mustang Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Mustang Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares69.4 M87.9 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted69.4 M87.9 M
Significantly Down
Slightly volatile
Total Assets108.6 M125.2 M
Fairly Down
Slightly volatile
Total Liabilities12.4 M12.8 M
Fairly Down
Slightly volatile
Current Assets97.2 M111.7 M
Fairly Down
Slightly volatile
Current Liabilities9.6 M10.8 M
Fairly Down
Slightly volatile
Total Debt2.1 MM
Fairly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Mustang Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Mustang Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Mustang Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mustang Bio's financial leverage. It provides some insight into what part of Mustang Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Mustang Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Mustang Bio deploys its capital and how much of that capital is borrowed.
Mustang Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.03 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Mustang Bio has a current ratio of 10.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mustang Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Mustang Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mustang Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mustang to invest in growth at high rates of return. When we think about Mustang Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(55.08 Million)Share
Mustang Bio (MBIO) is traded on NASDAQ Exchange in USA. It is located in 377 Plantation Street and employs 102 people. Mustang Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 66.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mustang Bio's market, we take the total number of its shares issued and multiply it by Mustang Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Mustang Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 92.58 M outstanding shares of which 3.78 M shares are now shorted by private and institutional investors with about 4.34 trading days to cover. Mustang Bio currently holds about 109.62 M in cash with (53.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Mustang Bio Probability Of Bankruptcy
Mustang Bio holds a total of 92.58 Million outstanding shares. Mustang Bio holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Mustang Ownership Details

Mustang Stock Price Odds Analysis

What are Mustang Bio's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Mustang Bio jumping above the current price in 90 days from now is about 85.8%. The Mustang Bio probability density function shows the probability of Mustang Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.469. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Mustang Bio will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Mustang Bio is significantly underperforming DOW.
  Odds Below 0.69HorizonTargetOdds Above 0.69
14.14%90 days
Based on a normal probability distribution, the odds of Mustang Bio to move above the current price in 90 days from now is about 85.8 (This Mustang Bio probability density function shows the probability of Mustang Stock to fall within a particular range of prices over 90 days) .

Mustang Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Mustang Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mustang Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mustang Bio's value.
InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares5.7 M5.7 M
Vanguard Group IncCommon SharesMM
View Mustang Bio Diagnostics

Mustang Bio Historical Income Statement

Mustang Bio Income Statement is one of the three primary financial statements used for reporting Mustang's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Mustang Bio revenue and expense. Mustang Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Interest Expense is expected to rise to about 15.4 K this year, although the value of Consolidated Income will most likely fall to (68.1 M). View More Fundamentals

Mustang Stock Against Markets

Picking the right benchmark for Mustang Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Mustang Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Mustang Bio is critical whether you are bullish or bearish towards Mustang Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mustang Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Investing Mustang Bio

You need to understand the risk of investing before taking a position in Mustang Bio. The danger of trading Mustang Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Mustang Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Mustang Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Mustang Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Mustang Bio information on this page should be used as a complementary analysis to other Mustang Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Mustang Stock analysis

When running Mustang Bio price analysis, check to measure Mustang Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mustang Bio is operating at the current time. Most of Mustang Bio's value examination focuses on studying past and present price action to predict the probability of Mustang Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mustang Bio's price. Additionally, you may evaluate how the addition of Mustang Bio to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Mustang Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Mustang Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.